

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

**PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): **October 22, 2004**

ImmunoGen, Inc.

(Exact name of registrant as specified in its charter)

Massachusetts
(State or other
jurisdiction of
incorporation)

0-17999
(Commission
File Number)

04-2726691
(IRS Employer
Identification No.)

128 Sidney Street, Cambridge, MA 02139
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: **(617) 995-2500**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 5.02. DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS.

- (a) Not applicable.
- (b) and (c):

On October 25, 2004, ImmunoGen, Inc. announced the appointment of Christopher U. Missling, PhD, to the position of Chief Financial Officer, effective on October 25. Dr. Missling, age 39, served as Senior Vice President of Strategic Analysis and Planning of Curis, Inc. from December 2003 to July 2004 and as Chief Financial Officer of Curis, Inc. from August 2002 to November 2003. Dr. Missling served as Chief Financial Officer at Axaron Bioscience AG from November 2001 to July 2002. From January 2000 to October 2001 Dr. Missling was the Head of Financial Planning Aventis Group at Aventis SA and in the same position at Hoechst AG from July 1997 to December 1999. Dr. Missling has entered into no transactions with ImmunoGen of the kind that would require disclosure under Item 404(a) of Regulation S-K. Dr. Missling's base salary will be at a rate of \$240,000 per year. Dr. Missling was awarded a grant of 100,000 stock options which will vest at a rate of 25 percent per year for four years beginning on the first anniversary of his effective date of employment with ImmunoGen. The per share exercise price for these options will be the closing sale price of the Company's common stock on the effective date of employment, or \$5.15. Additionally, Dr. Missling will be eligible for an annual cash bonus of up to 30% of his annual salary.

Virginia A. Lavery, Vice President, Finance and Treasurer, will leave ImmunoGen effective October 22, 2004 to pursue other interests. On that date, Ms. Lavery and the Company entered into a separation agreement. The separation agreement provides Ms. Lavery severance pay in an amount equal to 6 months of her gross weekly base salary of \$3,693.80, less all applicable federal, state, local and other employment-related deductions.

- (d) Not applicable.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS

Exhibit No.

Exhibit

99.1

Press Release of ImmunoGen, Inc. dated October 25, 2004

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 27, 2004

ImmunoGen, Inc.

(Registrant)

/s/ Mitchel Sayare

Mitchel Sayare
Chairman of the Board and Chief Executive
Officer

3

EXHIBIT INDEX

| Exhibit No. | Exhibit |
|--------------------|----------------|
|--------------------|----------------|

| | |
|------|---|
| 99.1 | Press Release of ImmunoGen, Inc. dated October 25, 2004 |
|------|---|

4

IMMUNOGEN, INC.

128 Sidney Street, Cambridge, MA 02139-4239

TEL: (617) 995-2500 FAX: (617) 995-2510

Contacts:

Carol Hausner (Investors)
Executive Director, Investor Relations and
Corporate Communications
Tel: (617) 995-2500
info@immunogen.com

Tony Loke (Media)
Rx Communications Group, LLC
Tel: (917) 322-2164
tloke@rxir.com

FOR IMMEDIATE RELEASE

ImmunoGen, Inc. Appoints Christopher U. Missling as Chief Financial Officer

CAMBRIDGE, MA, October 25, 2004 – ImmunoGen, Inc. (Nasdaq: IMGN) today announced the appointment of Christopher U. Missling, PhD, as Chief Financial Officer, effective today.

Mitchel Sayare, PhD, Chairman and CEO, commented, “I am delighted to welcome Christopher to our management team. He has a unique combination of experience in the biotech and pharmaceutical industry, in banking, and in science that makes him particularly well suited to helping us take ImmunoGen to the next level.”

Dr. Missling brings to ImmunoGen previous experience as a Chief Financial Officer gained at the publicly-traded US biotechnology company, Curis, Inc., and at the private European biotechnology company, Axaron Bioscience AG. Prior to that, Dr. Missling was Head of Financial Planning at the multinational pharmaceutical company, Aventis, and at its predecessor, Hoechst AG. Before joining Hoechst, Dr. Missling held positions of increasing responsibility at Deutsche Bank and its affiliates, and was an analyst in the pharmaceutical/healthcare investment banking group of Deutsche Morgan Grenfell. Dr. Missling received his MBA from Northwestern University’s Kellogg School of Management and his PhD in Chemistry from the Ludwig-Maximilians-University, Munich.

Virginia Lavery, Vice President, Finance and Treasurer, will leave ImmunoGen to pursue other interests.

“I would like to thank Ginger for the enormous contribution she has made to ImmunoGen,” said Dr. Sayare. “I know I speak for all of us at ImmunoGen when I say that we wish her well in her future endeavors.”

-more-

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer biopharmaceuticals. The Company’s proprietary Tumor-Activated Prodrug (TAP) technology uses tumor-targeting monoclonal antibodies to deliver a potent cell-killing agent specifically to cancer cells. Two ImmunoGen-developed TAP products have begun clinical evaluation: cantuzumab mertansine and huN901-DM1. Aventis, Genentech, Biogen Idec, Boehringer Ingelheim, and Millennium Pharmaceuticals, Inc. have licensed the right to develop TAP compounds to specific targets; ImmunoGen also has a broader collaboration with Aventis. Two partner-developed TAP compounds have entered clinical testing: bivatuzumab mertansine, developed by Boehringer Ingelheim, and MLN2704, developed by Millennium.
